[Featured Stock] SCM Life Sciences Plummets Over 24% Following Clinical Trial Failure News

[Asia Economy Reporter Minji Lee] SCM Life Sciences is experiencing a drop of over 20% during trading hours. The news that the acute pancreatitis stem cell treatment 'SCM-AGH' failed to demonstrate statistical significance in its Phase 1/2a clinical trials has had an impact.

At 2:29 PM on the 1st, SCM Life Sciences was trading at 9,590 KRW, down 24% from the previous trading day. The stock price fell as low as 9,530 KRW during the session.

The company announced the previous day that although it completed the Phase 1/2a clinical trials for the acute pancreatitis stem cell treatment 'SCM-AGH' under development, it failed to prove statistical significance for the primary efficacy endpoint.

The company explained that statistical significance was not confirmed between the test group (17 patients) who received SCM-AGH and the placebo group (14 patients) who received a placebo in the primary efficacy evaluation variable, 'CTSI (Computed Tomography Severity Index) on day 28 after administration of the investigational drug.'

This content was produced with the assistance of AI translation services.